5-Fluorouracil (5-FU)
Brand Name: Adrucil
Manufacturer: Accord Healthcare, Generic Medical Partners Inc.
Indication
Indication:
Used for the treatment of colorectal cancer, primarily in combination with other chemotherapy agents for both adjuvant and metastatic settings. It is commonly used with leucovorin to enhance antitumor activity and forms the backbone of standard regimens such as FOLFOX (5-FU/leucovorin/oxaliplatin), FOLFIRI (5-FU/leucovorin/irinotecan), and FOLFOXIRI.
Specific CRC Subtype: None
Stage: II, III, IV
Therapy Line: First-line, Third-line or later
Health Canada Approval: Approved
pCPA Negotiation Status:
Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)
New Search
